Deadline: 02-Jun-2026
Pfizer is offering Quality Improvement grants in Kazakhstan to strengthen oncology data systems and precision cancer care. Eligible healthcare organisations can apply for funding between 5,000,000 and 10,000,000 KZT for projects lasting 1–2 years, focusing on data quality, diagnostics integration, and evidence-based care.
Overview
Pfizer has launched a competitive Quality Improvement (QI) grant programme to enhance oncology data systems and precision care delivery in Kazakhstan.
The initiative focuses on improving how cancer-related data is collected, managed, and used to support better clinical decision-making and population health insights.
Key Grant Details
- Funding Organisation: Pfizer
- Geographic Focus: Kazakhstan
- Grant Type: Quality Improvement (non-clinical research)
- Funding Amount: 5,000,000 to 10,000,000 KZT per project
- Project Duration: 1 to 2 years
- Scope: National or regional
- Collaboration: Multi-site projects encouraged
Program Objectives
The programme aims to strengthen precision oncology systems through better data and care processes.
Core Objectives
- Improve collection and standardisation of oncology data
- Enable data linkage across the patient care pathway
- Integrate molecular diagnostics and biomarkers into treatment decisions
- Enhance data governance and quality frameworks
- Improve diagnostic and testing pathways
- Support population-level insights for epidemiology and health planning
Key Concept: Precision Oncology
Precision oncology refers to tailoring cancer treatment based on individual patient data, including genetic or molecular characteristics (biomarkers), rather than using a one-size-fits-all approach.
Focus Cancer Areas
Projects should focus on advanced cancers where precision diagnostics are critical:
- Advanced lung cancer (adult)
- Metastatic breast cancer
- Metastatic prostate cancer
What Types of Projects Are Supported?
This is a Quality Improvement (QI) programme, not a research grant.
Supported Activities
- Data system improvement and integration
- Implementation of diagnostic pathways
- Biomarker testing integration into care
- Data quality and registry enhancements
- Health system workflow improvements
Not Supported
- Clinical trials
- Drug efficacy or safety studies
- Pure academic or theoretical research
Who is Eligible?
Eligible Organisations
- Medical, dental, nursing, and pharmacy schools
- Healthcare institutions (hospitals, clinics)
- Professional medical organisations
- Government agencies
- Health-focused non-profits or institutions
Ineligible Applicants
- Individual applicants
- Independent medical practice groups
Mandatory Requirements
Applicants must:
- Be legally able to receive funding from Pfizer International LLC
- Apply as an organisation (not individual-led funding)
- Appoint a project lead who is:
- An employee or authorised representative
- Responsible for project delivery
Collaboration Requirements
- Multi-partner collaborations are encouraged
- Each partner must have a clearly defined role
- A lead organisation must take full responsibility
How the Grant Works
Step-by-Step Process
- Identify gaps in oncology data systems or care pathways
- Design a Quality Improvement project aligned with programme objectives
- Define measurable outcomes (data quality, integration, diagnostics use)
- Build partnerships if applying collaboratively
- Prepare and submit the proposal through Pfizer’s grant system
- If selected, implement the project within 1–2 years
- Monitor and report outcomes related to system improvement
Why This Grant Matters
This initiative is critical because it:
- Strengthens data-driven cancer care systems
- Improves early and accurate diagnosis using biomarkers
- Enables better health system planning and epidemiology insights
- Supports scalable improvements in oncology care delivery
It addresses a major gap in many healthcare systems: fragmented and underutilised oncology data.
Common Mistakes to Avoid
- Proposing clinical research instead of quality improvement
- Lack of clear data integration strategy
- Weak measurement or evaluation framework
- अस्पष्ट roles in collaborative projects
- عدم alignment with precision oncology objectives
Practical Tips
- Focus on real-world system improvements
- Use measurable indicators (e.g., data completeness, turnaround time)
- Clearly integrate diagnostics into care pathways
- Ensure strong governance and data standards
Frequently Asked Questions (FAQs)
1. What is the funding range?
Projects can receive between 5,000,000 and 10,000,000 KZT.
2. What type of projects are eligible?
Only Quality Improvement projects focused on oncology data and care systems.
3. Are clinical trials allowed?
No, clinical research and drug evaluation studies are not supported.
4. Who can apply?
Healthcare organisations, academic institutions, government bodies, and professional organisations.
5. Can individuals apply?
No, only organisations are eligible.
6. Is collaboration required?
Not mandatory, but multi-site collaborations are encouraged.
7. What is the project duration?
Projects should last between 1 and 2 years.
Conclusion
The Pfizer Oncology Quality Improvement Grant in Kazakhstan is a high-impact opportunity for healthcare organisations to enhance precision cancer care through better data systems. By focusing on integration, diagnostics, and real-world care improvements, the programme supports scalable and sustainable changes in oncology delivery.
Organisations with strong implementation plans, clear data strategies, and measurable outcomes are best positioned to secure funding and drive meaningful impact.
For more information, visit Pfizer.